Methylprednisolone
A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.
Molekularmasse
374,4710 g/mol
LogP
1,90
TPSA
94,80 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Intermediate-acting synthetic glucocorticoid.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Intermediate-acting synthetic glucocorticoid.
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
InChI
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
Molecular Formula
C22H30O5
HBD / HBA
3 / 5
Rotierbare Bindungen
2
Schwere Atome
27
Diltiazem inhibits CYP3A4-mediated methylprednisolone metabolism, increasing methylprednisolone exposure and the risk of steroid side effects including immunosuppression, hyperglycaemia, and hypertension.
Fluconazole inhibits CYP3A4-mediated metabolism of methylprednisolone, increasing its plasma levels and prolonging corticosteroid effects, raising the risk of Cushingoid features.
Methylprednisolone inhibits CYP3A4-mediated cyclosporine metabolism, raising cyclosporine levels; conversely, cyclosporine may increase methylprednisolone exposure — a bidirectional pharmacokinetic interaction.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.
Intermediate-acting synthetic glucocorticoid.
Key pharmacokinetic parameters for Methylprednisolone: Half-life: 18-36 hours.
Yes, Methylprednisolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL650. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6741. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="methylprednisolone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/methylprednisolone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/methylprednisolone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/methylprednisolone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="methylprednisolone"></drugfyi-drug>